Source:		MedGen UID: 299170


			A recombinant, humanized IgG1 monoclonal
			antibody directed against the
			interleukin-6 receptor (IL-6R) with
			immunosuppressant activity. Tocilizumab
			targets and binds to both the soluble form of
			IL-6R (sIL-6R) and the membrane-bound form
			(mIL-6R), thereby blocking the binding of IL-6
			to its receptor. This prevents IL-6-mediated
			signaling. Il-6, a pro-inflammatory cytokine that
			plays an important role in the regulation of the
			immune response, is overproduced in
			autoimmune disorders and certain types of

			Related Concepts
			rheumatoid arthritis
			disease-modifying antirheumatic drugs
			cytokine release syndrome
			juvenile idiopathic arthritis
			giant cell arteritis

			PRJNA134351 Combination of peripheral blood
			gene expression profiles and clinical
			parameters predicts response for tocilizumab
			(anti-IL6) treatment in rheumatoid arthritis

			PRJNA196517 Effects of tocilizumab versus
			methotrexate therapy on gene expression
			profiles in the early rheumatoid arthrtis

			PRJNA113057 Gene Expression Analysis in
			Peripheral Blood of Patients with Rheumatoid

			PRJNA196596 Genome-wide analysis of EGFR
			inhibitor erlotinib treatment in Head and neck,
			squamous cell carcinoma's FADU, SQ20B and
			Cal 27

			PRJNA152397 Human peripheral blood cells
			(PB): Effect of Tocilizumab/MRA compared to
			methotrexate(MTX) treatments on rheumatoid
			arthritis(RA) patients.

			PRJNA312528 Identification of baseline gene
			expression signatures predicting therapeutic
			responses to three biologic agents in
			rheumatoid arthritis: a retrospective
			observational study

			PRJNA307567 Mitochondrial and oxidative
			stress genes are differentially expressed in
			neutrophils of sJIA patients treated with
			tocilizumab: a pilot microarray study

			PRJNA416370 Skin gene expression is
			prognostic for the trajectory of skin disease in
			patients with diffuse cutaneous systemic

			PRJNA360442 Whole blood gene expression
			of rheumatoid arthritis

			32341791 Thoughts on COVID-19 and
			autoimmune diseases.

			32320677 Complex Immune Dysregulation in
			COVID-19 Patients with Severe Respiratory Failure.

			32309629 Efficacy and Safety of Tocilizumab
			in the Treatment of Acute Active Antibody-mediated
			Rejection in Kidney Transplant Recipients.

			32305359 American Society for Transplantation
			and Cellular Therapy Pharmacy Special Interest
			Group Position Statement on Pharmacy Practice
			Management and Clinical Management for
			COVID-19 in Hematopoietic Cell Transplantation
			and Cellular Therapy Patients in the United

			32303241 The French paediatric cohort of
			Castleman disease: a retrospective report of
			23 patients.

			32293545 Treatment modalities and drug
			survival in a systemic sclerosis real-life patient

			32280950 Tocilizumab in patients with anti-TNF
			refractory juvenile idiopathic arthritis-associated
			uveitis (APTITUDE): a multicentre, single-arm,
			phase 2 trial.

			32274443 Concomitant herpes simplex keratitis
			and autoimmune-associated ulcerative keratitis
			in rheumatoid arthritis patients.

			32271899 Grading and management of
			cytokine release syndrome in patients treated
			with tisagenlecleucel in the JULIET trial.

			32267094 Comparative Risk of Diabetes Mellitus
			in Patients With Rheumatoid Arthritis Treated
			With Biologic or Targeted Synthetic
			Disease-Modifying Drugs: A Cohort Study.

			32253068 Recommendations for
			coronavirus infection in rheumatic diseases
			treated with biologic therapy.

			32249274 Thrombocytopenia, Anasarca,
			Fever, Reticulin Fibrosis/Renal Failure, and
			Organomegaly (TAFRO) Syndrome with Bilateral
			Adrenal Hemorrhage in Two Caucasian Patients.

			32248829 Effectiveness of TOcilizumab in
			comparison to Prednisone In Rheumatoid Arthritis
			patients with insufficient response to
			disease-modifying antirheumatic drugs (TOPIRA):
			study protocol for a pragmatic trial.

			32247050 Insight into 2019 novel coronavirus
			- an updated intrim review and lessons from
			SARS-CoV and MERS-CoV.

			32234467 The cytokine release syndrome
			(CRS) of severe COVID-19 and Interleukin-6 receptor
			(IL-6R) antagonist Tocilizumab may be the key
			to reduce the mortality.

			32222713 A Case of Novel Coronavirus Disease
			19 in a Chronic Hemodialysis Patient Presenting
			with Gastroenteritis and Developing Severe
			Pulmonary Disease.

			32210531 Giant Cell Arteritis: The Experience
			of Two Collaborative Referral Centers and an
			Overview of Disease Pathogenesis and
			Therapeutic Advancements.

			32201660 Organizing Pneumonia Induced by
			Tocilizumab in a Patient with
			Rheumatoid Arthritis.

			32188441 Severe sepsis caused by serious
			gastrointestinal infection in sJIA patients treated
			with IL-6 receptor antagonist: a case report.

			32185362 Persistence and Adherence during
			the First Six Months of Tocilizumab Treatment
			Among Rheumatoid Arthritis Patients in Routine
			Clinical Practice in Greece. Results from the
			Single Arm REMISSION II Study

			32185340 Treatment of systemic sclerosis
			associated fibrotic manifestations: Current
			options and future directions.

			32185277 Study of the natural course and
			specific immunity after herpes zoster in patients
			with rheumatoid arthritis receiving biologic

			32183689 European Headache Federation
			recommendations for neurologists managing
			giant cell arteritis.

			31249756 Early Initiation of Tocilizumab in
			Clinically Isolated Aortitis.

			31246724 Recurrent Stroke in Giant Cell
			Arteritis Despite Immunotherapy.

			31246342 LNRRIL6, a novel long non-coding
			RNA, protects colorectal cancer cells by
			activating the IL-6-STAT3 pathway.

			31244353 Successful treatment with
			tocilizumab for massive ascites due to
			secondary amyloidosis complicating
			rheumatoid arthritis: a case report.

			31243259 Tocilizumab and rituximab have
			similar effectiveness and are both superior to a
			second tumour necrosis factor inhibitor in
			rheumatoid arthritis patients who discontinued
			a first TNF inhibitor.

			31230059 Tocilizumab in refractory juvenile
			idiopathic arthritis with associated uveitis: a
			case report.

			31223480 Effects of interleukin-6 receptor
			blockade on allergen-induced airway responses
			in mild asthmatics.

			31219357 Tocilizumab for the treatment of
			chimeric antigen receptor T cell-induced
			cytokine release syndrome.

			31213436 Remission maintenance after
			tocilizumab dose-tapering and interruption in
			patients with giant cell arteritis: an open-label,
			18-month, prospective, pilot study.

			31209481 Drug retention of biological DMARD
			in rheumatoid arthritis patients: the role of
			baseline characteristics and disease evolution.

			31204508 Comparison of adverse events of
			biologicals for treatment of juvenile idiopathic
			arthritis: a systematic review.

			31201793 Multiplexed monitoring of
			therapeutic antibodies for inflammatory
			diseases using Fab-selective proteolysis
			nSMOL coupled with LC-MS.

			31201070 Favorable Outcomes With Early
			Interleukin 6 Receptor Blockade in Severe
			Acute Necrotizing Encephalopathy of

			31196844 Initiating tocilizumab, with or without
			methotrexate, compared with starting
			methotrexate with prednisone within step-up
			treatment strategies in early rheumatoid
			arthritis: an indirect comparison of effectiveness
			and safety of the U-Act-Early and CAMERA-II
			treat-to-target trials.

			31187094 Tocilizumab in sarcoidosis patients
			failing steroid sparing therapies and anti-TNF

			31174825 Outcomes of patients with systemic
			sclerosis treated with tocilizumab: Case series
			and review of the literature.

			31174819 Central nervous system involvement
			in rheumatoid arthritis patients and the potential
			implications of using biological agents.

			31172726 The First Case Series of
			Cryopyrin-Associated Periodic Syndrome in

			31165299 The use of leukocytes' secretome to
			individually target biological therapy in
			autoimmune arthritis: a case report.

			31159524 [Efficacy and safety of tocilizumab in
			patients with Takayasu arteritis].

			Clinical Trials
			3970226 Tocilizumab in Children With ACP

			3967691 IL-6 Regulation of Substrate
			Metabolism and Influence of Obesity

			3933904 Sirolimus in Previously Treated
			Idiopathic Multicentric Castleman Disease

			3923738 A Study to Evaluate the
			Pharmacokinetics, Pharmacodynamics, and
			Safety of Tocilizumab (TCZ) Administered to
			Participants With Giant Cell Arteritis (GCA).

			3895879 Use of Tocilizumab Drug Levels to
			Optimize Treatment in RA

			3892785 MEthotrexate Versus TOcilizumab for
			Treatment of GIant Cell Arteritis: a Multicenter,
			Randomized, Controlled Trial

			3867617 Cell Therapy for Immunomodulation in
			Kidney Transplantation

			3863015 IL-6 Inhibition for Modulating
			Inflammation After Cardiac Arrest

			3859388 Longitudinal Changes in
			Donor-Derived Cell-Free DNA With Tocilizumab
			Treatment for Chronic Antibody-Mediated

			3787290 Mild-Intensity Whole Body
			Hyperthermia (WBH) for Major Depressive

			3781310 Therapeutic Drug Monitoring of
			Tocilizumab in Rheumatoid Arthritis

			3745586 Giant Cell Arteritis Treatment With
			Ultra-short Glucocorticoids and Tocilizumab

			3726749 Tocilizumab Plus a Short Prednisone
			Taper for GCA

			3711448 Ustekinumab for the Treatment of
			Relapse of Refractory Giant Cell Arteritis

			3699631 PROACTIVE: Prevention of Acute and
			Chronic GVHD Using TocIlizumab in
			Combination With Standard GVHD Prophylaxis
			After allogEneic Transplantation

			3644667 Tocilizumab in Cardiac

			3632187 Abatacept in earLy Onset Polymyalgia
			Rheumatica: Study ALORS

			3606876 Comparative Study to Evaluate the
			Pharmacokinetics of BAT1806 vs Actemra® in
			Healthy Subjects

			3588936 Nivolumab and Tocilizumab for
			Relapsed Hematological Malignancy
			Post-allogeneic Transplant

			3554161 Tocilizumab for the Treatment of
			Refractory Behcet's Uveitis

     		                         Embed       Tweet       Print